Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline
Tier C — Watch / tradeSitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline
Targets：DPP4, SGLT2
Brand：Sujanu
Indications (approved)：Type 2 diabetes
Regional status
Factories producing this API19
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
19 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates4 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| IPRA-001 | 93777-26-5Available | 5-bromo-2-fluorobenzaldehyde |
| IPRA-002 | 95-15-8 | benzo[b]thiophene |
| IPRA-003 | 1034305-11-7Available | benzo[b]thiophen-2-yl(5-bromo-2-fluorophenyl)methanol |
| IPRA-004 | 761424-75-3 | (benzo[b]thiophen-2-yl(5-bromo-2-fluorophenyl)methoxy)(tert-butyl)dimethylsilane |
| IPRA-005 | 13096-62-3Available | (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-one |
| IPRA-006 | - | (3R,4S,5R,6R)-2-(3-(benzo[b]thiophen-2-yl((tert-butyldimethylsilyl)oxy)methyl)-4-fluorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-ol |
| IPRA-007 | 761425-14-3 | (3R,4S,5R,6R)-2-(3-(benzo[b]thiophen-2-yl(hydroxy)methyl)-4-fluorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-ol |
| IPRA-008 | 761423-01-2 | (2S,3S,4R,5R,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran |
| Code | CAS No. | Intermediate |
|---|---|---|
| IPRA-001 | 93777-26-5Available | 5-bromo-2-fluorobenzaldehyde |
| IPRA-002 | 95-15-8 | benzo[b]thiophene |
| IPRA-003 | 1034305-11-7Available | benzo[b]thiophen-2-yl(5-bromo-2-fluorophenyl)methanol |
| IPRA-005 | 13096-62-3Available | (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-one |
| IPRA-008 | 761423-01-2 | (2S,3S,4R,5R,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran |
| IPRA-009 | 1034305-17-3Available | 2-(5-bromo-2-fluorobenzyl)benzo[b]thiophene |
| IPRA-010 | - | (3R,4S,5R,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-ol |
| Code | CAS No. | Intermediate |
|---|---|---|
| IPRA-009 | 1034305-17-3Available | 2-(5-bromo-2-fluorobenzyl)benzo[b]thiophene |
| IPRA-017 | 74372-90-0 | (1S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-3-((benzyloxy)methyl)-2,7-dioxabicyclo[4.1.0]heptane |
| IPRA-018 | 1825379-70-1 | (2S,3S,4R,5R,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-3-ol |
| Code | CAS No. | Intermediate |
|---|---|---|
| IPRA-001 | 93777-26-5Available | 5-bromo-2-fluorobenzaldehyde |
| IPRA-002 | 95-15-8 | benzo[b]thiophene |
| IPRA-003 | 1034305-11-7Available | benzo[b]thiophen-2-yl(5-bromo-2-fluorophenyl)methanol |
| IPRA-009 | 1034305-17-3Available | 2-(5-bromo-2-fluorobenzyl)benzo[b]thiophene |
| IPRA-011 | 1034305-19-5 | 2-((5-bromo-2-fluorophenyl)chloromethyl)benzo[b]thiophene |
| IPRA-012 | 32384-65-9Available | (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one |
| IPRA-013 | 1034305-23-1 | (2S,3R,4S,5S,6R)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol |
| IPRA-014 | 1034305-27-5 | (2S,3R,4S,5R,6R)-6-(acetoxymethyl)-2-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate |
| IPRA-015 | 1034305-21-9Available | (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-(benzo[b]thiophen-2-ylmethyl)-4-fluorophenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate |
| IPRA-016 | 147-85-3 | (S)-pyrrolidine-2-carboxylic acid |
Frequently asked questions
What are the approved indications of Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline?
Approved indications include: Type 2 diabetes.
When does the Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline patent expire?
No public expiry year is available for Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline yet; this page updates once verified.
How many synthesis routes are recorded for Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline?
4 synthesis routes are recorded; the shortest is 1 steps with 3.58 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline intermediates?
6 intermediate CAS of Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29